$HALO Tale of the Tape


Can Halozyme Therapeutics (HALO) Run Higher on Strong Earnings Estimate Revisions? – Tale of the Tape

Halozyme Therapeutics, Inc. (HALO) is a biotechnology company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on HALO’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Halozyme Therapeutics could be a solid choice for investors.

Current Quarter Estimates for HALO

In the past 30 days, 1 estimate have gone higher for Halozyme Therapeutics while 1 have gone lower in the same time period. The trend has been pretty favorable, with estimates narrowing from a loss of 12 cents a share 30 days ago, to a loss of 3 cents today, an impressive move of 75%.

Current Year Estimates for HALO

Meanwhile, Halozyme Therapeutics’ current year figures are also looking quite promising. The consensus estimate trend has seen a boost for this time frame, narrowing from a loss of 49 cents per share 30 days ago to a loss of 40 cents per share today, an increase of 18.4%.


Please enter your comment!
Please enter your name here